Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc., have submitted a new drug application with the FDA for sorafenib for patients with advanced renal cell carcinoma. Submission is based on an ongoing phase III trial suggesting that the drug doubled progression-free survival compared with patients receiving placebo.